The Prognostic Value of Molecular Testing

Video

Transcript:

Jonathan Trent, MD, PhD: The other thing I was thinking about are these different mutations in GIST [gastrointestinal stromal tumor] but also mutations in other types of sarcoma. Do you think there is any prognostic value or any rationale for doing those types of molecular testing to predict outcomes of patients?

Neeta Somaiah, MD: Of course, even in GIST itself, I think it’s more predictive of response. I think there is prognostic value for GIST mutations, but there is a little bit of controversy. People do think that if you have a KIT or exon 11 mutation, but again, even KIT exon 11 comes in different varieties. So depending on the type, some could have a prognostic significance in the sense that it’s thought to probably be more likely to recur, as opposed to say the PDGFR [platelet-derived growth factor receptor] or not having a mutation.

But for other sarcoma subtypes, I think there are data for desmoid tumors where the CTNNB1 mutation and certain mutations can have a worse prognosis. So there’s a little bit of prognostication that we get by getting mutation testing done in other subtypes. But I think it also more so helps us in figuring out the subtype better and predicting whether one treatment might work or not. And I think as we’re going in to more clinical trials that are subtype specific, these nuances about what mutations are important; like we knew about translocations such as Ewing sarcoma, the most common translocation, and then this new 6 ducts translocation emerged, which is not a Ewing sarcoma, but has a worse prognosis. So there are definitely prognostic implications for certain translocations in the other subtypes as well that we use to determine whether it’s going to be a bad actor or a good actor, or figure out how to predict how this patient is going to do on certain therapies.

Jonathan Trent, MD, PhD: Yes, and the BCOR gene.

Neeta Somaiah, MD: Yes, the BCOR as well.

Jonathan Trent, MD, PhD: The BCOR also seems to prognosticate that patients may do a little bit better.

Neeta Somaiah, MD: Yes.

Jonathan Trent, MD, PhD: I think that the presence of some of these molecular signatures may help us to figure out which subsets of patients we need to be more aggressive with, in terms of chemotherapy, and which subset of patients we need to be developing new agents for.

Neeta Somaiah, MD: Correct.

Jonathan Trent, MD, PhD: And I think that, regarding all of the molecular data we’re gathering today, in the next few years we’re going to be able to be more prognostic and predictive.

Neeta Somaiah, MD: I totally agree, and I think as you just mentioned before, that they’re now classified. We keep coming up with more subtypes of sarcoma because that’s true, once you understand the molecules better, they’re able to classify them better, and we’re able to understand why one performs differently than the others and they don’t all fall into 1 bucket.

Transcript Edited for Clarity

Related Videos
Christina L. Roland, MD, MS, FACS
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Related Content
Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet — Copenhagen University Hospital

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024
Article
Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

December 29th 2022
Podcast
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article